To evaluate the efficacy and safety of the investigational Lyme disease vaccine PF-07307405 in preventing Lyme disease.
Key Findings:
The vaccine demonstrated 73% efficacy in preventing Lyme disease starting 28 days after the fourth dose.
A secondary analysis indicated approximately 75% efficacy beginning one day after the fourth dose.
The vaccine was well tolerated with no safety concerns identified.
Interpretation:
Despite not meeting the pre-specified primary statistical criterion due to fewer cases than anticipated, the results suggest clinically meaningful efficacy and support the vaccine's potential.
Limitations:
The primary statistical criterion was not met.
Fewer-than-anticipated Lyme disease cases may limit the robustness of the findings.
Conclusion:
Pfizer plans to submit the vaccine for regulatory approval based on the promising efficacy results from the VALOR trial.
